We are delighted to share with you that PHARMAC announced today that it will fund two new treatments for Multiple Sclerosis. After years of funding submissions, culminating in a campaign this year led by MSNZ, PHARMAC has approved funding for two new treatments and increased access to those currently funded for New Zealander’s diagnosed with relapsing remitting forms of Multiple Sclerosis. Biogen Idec’s Natalizumab (trading as Tysabri) and Novartis’ Fingolimod (Gilenya) will be funded from 1 November 2014. PHARMAC has also approved increased access to currently-funded treatments in today’s announcement. Thank you to everyone who has been involved with this campaign. Many hours of work with some very dedicated people has gone into this successful step forward for MS in New Zealand. All the letters that were written, submissions made and YOUR support helped to feed the drive and success of this campaign. While the entry and exit criteria is still restrictive the changes that have been made make treatments much more accessible. The result is a positive one. We will continue working with PHARMAC to increase treatment options for people living with MS. Thank you once again for all your support. To read the full press release from MSNZ visit msnz.org.nz/Page.aspx?pid=296 Further information about PHARMACs decision, the criteria for funding and answers to questions made in submissions to the August Proposal can be found at pharmac.health.nz/news/notification-2014-10-10-mstreatments/
Posted on: Fri, 10 Oct 2014 03:31:48 +0000
Trending Topics
Recently Viewed Topics
© 2015